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Abstract
Before the discovery of insulin therapy in 1921 and the 
development of effective oral hypoglycaemic therapy in 
1926, pharmacological management of diabetes mellitus was 
restricted to empirical treatment often based on plant products 
and relegated to folklore medicine. One therapy reputed in 
Malta as useful for the management of diabetes mellitus in 
1927 was Fenugreek. This has now been shown to have definite 
pharmacological properties that controls blood glucose levels 
in diabetic subjects. 
Introduction
The history of diabetes mellitus has its beginning in 
antiquity, and this disease has apparently plagued man for a 
very long time, since the writings from the earliest civilisations 
refer to boils and infections, excessive thirst, loss of weight, and 
the passing of large quantities of honey-sweet urine which often 
drew ants and flies. There is a reference to the disease in the 
Ebers Papyrus dating back to 1500 BC, which recommended 
that those afflicted with the malady go on a diet of beer, fruits, 
grains, and honey, which was reputed to stifle the excessive 
urination. The mainstay of managing the disorder remained 
primarily dietary based on two schools of thought. One school 
believed in dietary replacement of the sugar lost in the urine, 
while the other believed in restriction of carbohydrate so as to 
reduce the effects which were attributed to an excess of sugar. 
Adjuvant pharmacological management in the early decades of 
the nineteenth century remained restricted to regimens utilizing 
plant products such as opium and scammony, and mineral 
products such as magnesium hydroxide and sodium phosphate 
and calomel [mercurous chloride]. These supplemented the use 
of venesection, emetics and stimulants.1 The breakthrough in 
the pharmacological management of diabetes was made in 1921 
after F.G. Banting and C.H. Best obtained extracts of insulin 
and administered the hormone to Leonard Thompson on the 
11th January 1922 in the Toronto General Hospital. The first oral 
biguanide hypoglycaemic, Synthalin,  was developed by the drug 
company Schering in 1926-27. This was eventually modified to 
Phenformin in 1957. The sulphonylureas were derived from the 
sulphonamides and marketed after 1955.
Pharmacological treatment 
of diabetes in Malta
Medical practitioners in Malta were long familiar with 
diabetes, with the first local case being documented in 1782 by 
Dr. Giuseppe Demarco who in his manuscript notes described 
a case of a nun suffering from diabetes and who in the space 
of ninety-four days voided 3594 chamber-pots of urine. His 
reference to contemporary medical literature confirms that Dr. 
Demarco was familiar with the literature.2 The cause-specific 
mortality rate from the disease in 1834 amounted to about 4.9 
per 100,000 population.3 Developments in the pharmacological 
management of diabetes were followed by Maltese practitioners 
during the subsequent decades of the nineteenth century. The 
Maltese medical journal Il Filocamo on the 1st September 1841 
published a summary of a paper previously published in a 
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foreign medical journal about the pharmaceutical management 
of diabetes using pills containing iron sulphate, zinc sulphate 
and extract of gentian. The editor, Prof. Schinas, observed 
that diabetes “was an illness very often resistant to the most 
rational and active forms of treatment ….. and because the 
essential nature of it was still unknown and, therefore, until this 
is determined one could not devise ways of curing it.”4 In 1890, 
the Maltese medical journal La Rivista Medica reviewed a paper 
read by Dr. F.W. Pavy at the International Medical Congress 
held in Berlin in August who advocated the administration of 
opium, codeine and morphine to further reduce the sugar levels.5 
The subsequent year, La Rivista Medica reported the work of 
Dr. N. Casarelli, published in the Rivista generale italiana 
di Clinica medica, with the use of the hypnotic Sulphonal 
(Sulfonmethane - C7H16O4S2) in diabetes mellitus which had been 
shown to exert a favourable influence on diabetes.6 In 1893, the 
medication known as China anti-diabetica, which consisted of 
a tonic element extracted from the plant Cinchona officinalis 
(Quinine Bark) and an anti-diabetic basis (redistilled glycerine 
of great purity) was being advocated and imported for sale in 
local pharmacies.7 The pharmacist Francesco Caruana Dingli in 
1899 manufactured an anti-diabetic medication Nuovo Liquore 
Anti-diabetico claimed to be “an infallible and very quick acting 
remedy against diabetes even in its most resistant form.” This 
had been examined and approved by Prof. V. Micallef, Professor 
of Chemistry and Government Analyst.8 In the first decade of the 
twentieth century, another locally prepared anti-diabetic agent 
Fermentina was being marketed.9 The contents of the latter 
two agents are unknown. Effective pharmacological therapies 
were introduced by the Professor of Surgery P.P. Debono, who 
in June 1923 reviewed the use of insulin finding it useful in 
cases of diabetic coma, the juvenile form of diabetes, diabetics 
with infections or undergoing surgery, and in those cases who 
could not be kept on a sugar-free diet. Because of the high 
cost associated with the medication and its control, insulin 
therapy was still restricted to those who could afford to buy 
the medication or were in-patients in the hospital.10 In 1927, 
the Professor of Medicine J.E. Debono outlined the principles 
of diabetic management with the mainstay of treatment 
remaining a maintenance-diet that contains just enough calories 
to maintain life and health. Insulin by injection was added to 
the management if glucosuria persisted after a week of dietary 
control. He considered all insulin substitutes available at the 
time to be “absolutely valueless.” However Synthalin, then still 
under investigation, was mentioned as a possible substitute to 
insulin in mild cases in spite of its toxic effects.11 
Phytotherapy 
The inadequacy of available pharmacological agents gave 
rise to folkloric herbal medicine often without a pharmacological 
basis (Table 1). In 1927, the year when the first biguanide was 
being investigated, the Professor of Natural History J. Borg 
in his list of Maltese flora reports that the seeds of the species 
Trigonella foenum-graecum Linn (English: fenugreek, Italian: 
fienu-greco; Maltese: helba or fienu; Arabic: hulba or hilbeh) 
Scientific	name	 English	vernacular
Trigonella foenum graecum Fenugreek, Greek hayseed
Cichorium intybus Chicory
Cichorium spinosum
Cynara scolymus Globe artichoke
Helianthus tuberosus Jerusalem artichoke
Helianthus annuus Sunflower
Urtica urens Nettle, Stinging nettle
Olea europea Olive
Table 1: Plants believed to be useful for diabetes 
in Maltese and Moroccan Medical Folklore
as being a supposed cure for diabetes.12 The plant, a member of 
the pea family (Family: Fabaceae – Leguminosae), is a native of 
southern Europe, the Mediterranean region, and Western Asia, 
but has been extensively cultivated elsewhere. Prof. Borg 
believed the species to have been introduced and naturalized in 
Malta through cultivation. He reported it growing in the Girgenti 
and Siggiewi region. The species has however been known in 
the Maltese Islands since at least the mid-eighteenth century 
having been referred to by G.F. Agius de Soldanis in his 1750 
manuscript “Damma tal Kliem Kartaginis mscerred fel fom tal 
Maltin u Ghaucin”, and also by G. Gulia’s 1889-90 “Prontuario 
di Storia Naturale.” 13 
Fenugreek seeds have been used medicinally all through 
the ages and were held in high repute among the Egyptians, 
Greeks and Romans for medicinal and culinary purposes. In 
ancient Egypt, fenugreek was used to ease childbirth and to 
increase milk flow. Today, it is still taken by Egyptian women 
for menstrual pain and as “hilba tea” to ease stomach problems 
of tourists. Therapeutically, in 1905, the seeds of the plant were 
reportedly employed for the preparation of emollient poultices, 
enemata, ointments and plasters. They were not recommended 
for use internally, presumably excluding their use in diabetes.14 
In common with other legumes, fenugreek seeds are high in 
protein with a 100 g of seeds supplying about 23 g of protein. 
In the Middle East, boiled fenugreek seeds are served as a 
high protein main dish. The seeds are also rich in vitamin and 
minerals. The seeds also contain the vanilla-scented coumarin, 
making them useful for food flavoring as components of curry 
powders and chutneys. Its traditional medical properties come 
for the presence of mucilage, an emollient soothing to the skin. 
Fenugreek seeds further contain a wide range of components 
including trigonelline that when heated yields nicotinic acid 
(100 g of seed yields 1.6 mg of nicotinic acid – about 10% of 
the recommended requirements); and diosgenin that can be 
converted to pregnenolone and progesterone. The seeds have 
traditionally been considered to have expectorant, demulcent, 
emollient, febrifuge, carminative, nutritive, tonic, mucilaginous, 
restorative, anti-inflammatory, diuretic, stimulant, laxative, and 
stomachic functions. The aerial parts were further attributed 
with antispasmodic properties.15 
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Numerous animal studies and preliminary trials in humans 
over the last two decades have found that fenugreek can reduce 
blood sugar and serum cholesterol levels in people with both 
type 1 and type 2 diabetes.16,17,18 The mode of action of fenugreek 
in improving metabolic control in diabetic subject is still not 
clear. It has been suggested that Fenugreek acts by reducing 
the rate of gastric emptying thus inhibiting glucose transport 
and intestinal glucose absorption.19 Further studies have also 
attributed the seeds with secretagogue actions, similar to those 
of glibenclamide, stimulating insulin synthesis and/or secretion 
from the beta pancreatic cells of Langerhans.20 An extra-
pancreatic mode of action by increasing the sensitivity of tissues 
to available insulin for the active principle of fenugreek seeds 
has also been demonstrated18. It has been suggested that the 
active hypoglycemic agent in fenugreek seed may be the amino 
acide 4-Hydroxyisoleucine. This amino acid has been shown to 
increase glucose-induced insulin release through a direct effect 
on isolated islets of Langerhans from both rats and humans. 
The stimulating effect of 4-hydroxyisoleucine was shown to be 
biphasic occurring in the absence of any change in pancreatic 
alpha- and delta-cell activity. The insulin response was 
dependant on the glucose concentration. The active ingredient 
did not interact with other agonists of insulin secretion such as 
leucine, arginine, tolbutamide, and glyceraldehyde.21 
Conclusions 
Many modern medications owe their origins to plant 
products, the classical examples being morphine extracted 
from the opium poppy and digitalis originally extracted from 
the foxglove plant. Some traditional therapeutic measures have 
been generally abandoned and relegated to medical folklore, 
particularly with the development of inorganically produced 
or modified pharmacologic agents. The use of fenugreek for 
diabetes is one such traditional measure that was superseded 
after the mid-1950s with the development of the biguanides 
and the sulphonylureas, which proved to be effective oral 
hypoglycaemic agents. It is only in recent years, that fenugreek 
has been scientifically investigated in relation to its anti-
diabetogenic properties and found to be effective in reducing 
blood sugar levels in mild diabetics. While no recommendation 
can at present be safely made to control diabetic patients with 
fenugreek, it may be opportune to re-introduce the legume in 
the local diet particularly in those individuals diagnosed to have 
impaired glucose tolerance or are at high risk of developing the 
metabolic syndrome.
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